Blog
Evidence-based articles on the conditions we treat, written for real people — not medical journals.
A head-to-head comparison of the two 5-alpha reductase inhibitors — DHT suppression, side effect signals, half-life, and when to switch.
Read article →Why oral is eating topical's lunch — efficacy, side effect comparison, adherence data, and who should pick which.
Read article →Month-by-month on finasteride and minoxidil — the dread shed, first response, peak results, and how to know when to evaluate.
Read article →Telehealth handles classic male pattern hair loss well — but these red flags need in-person dermatology: patchy loss, scarring, sudden shedding.
Read article →A calm, step-by-step playbook: call the pharmacy first, know when urgent care is worth it, and a decision tree for what you actually take.
Read article →Two terms that sound similar but mean different things — when each applies, who qualifies for a bridge, and where the model honestly falls short.
Read article →Records, 90-day supplies, which of your meds are time-sensitive, and a complete checklist for planning the handoff between doctors.
Read article →New antibiotic-sparing strategies, the truth about cranberry supplements, and why recurrent UTIs are finally getting the attention they deserve.
Read article →Why most over-the-counter treatments fail, what actually causes recurrence, and the emerging role of the vaginal microbiome in prevention.
Read article →New research on cardiovascular links, why ED may be an early warning sign, and how modern telehealth is changing access to treatment.
Read article →What to expect on day 1, day 3, and beyond — plus when to worry if your symptoms haven't cleared.
Read article →Yes — here's how async telehealth works, what it can't treat, and when you really do need an in-person visit.
Read article →What clinical safety checks actually matter, the drugs that shouldn't mix with sildenafil, and how to spot a sketchy online pharmacy.
Read article →What telehealth charges vs insurance urgent care vs cash-pay clinics — the honest breakdown, and why flat-fee is usually cheapest.
Read article →Symptoms overlap but treatments don't. Getting the wrong prescription can make it worse. Here's how providers tell them apart.
Read article →A clinician-reviewed comparison of the two most-prescribed UTI antibiotics — efficacy, resistance, side effects, and how providers choose.
Read article →Low-count bacteriuria, interstitial cystitis, STIs, and pelvic floor dysfunction all mimic a UTI. Here's how to pin down what's really happening.
Read article →Viagra's active ingredient vs Cialis's — side-by-side on onset, duration, daily vs on-demand dosing, and how to pick the right fit.
Read article →Recurrent candidiasis affects 8% of women. Here are the real causes — non-albicans species, diabetes, antibiotics — and what actually works.
Read article →What same-day async telehealth actually is, which conditions qualify, what it costs vs urgent care, and what won't work over the internet.
Read article →Urinary tract infections remain one of the most common bacterial infections worldwide, accounting for roughly 8 million clinic visits annually in the United States alone. But the way we understand and treat them is evolving fast. Here's what the latest research says — and what it means for your care.
One of the biggest shifts in UTI treatment is the growing awareness of antibiotic resistance. A 2024 study published in The Lancet Infectious Diseases found that resistance to trimethoprim-sulfamethoxazole (Bactrim) now exceeds 25% in many U.S. regions. This has led the American Urological Association to update its guidelines, emphasizing nitrofurantoin (Macrobid) as the preferred first-line treatment for uncomplicated UTIs.
"The era of empiric Bactrim for every UTI is over. Clinicians must consider local resistance patterns when selecting therapy."— Journal of Antimicrobial Chemotherapy, 2024
For decades, cranberry supplements have occupied a gray area between folk remedy and legitimate treatment. A large-scale 2023 meta-analysis in the New England Journal of Medicine reviewed 50 randomized controlled trials and found that cranberry products reduced the risk of recurrent UTIs by approximately 27% — a modest but real benefit.
The key caveat: the benefit was primarily seen in women with recurrent UTIs (three or more per year), not as a treatment for active infections. Cranberry supplements may help prevent the next UTI, but they won't cure the one you have now.
Historically, recurrent UTIs were treated with repeated rounds of antibiotics — sometimes low-dose prophylaxis for months. Newer research is exploring alternatives:
While some mild UTIs in healthy young women may resolve on their own, current evidence strongly favors early treatment. Untreated UTIs carry a 20–30% risk of ascending to the kidneys (pyelonephritis), which can become a serious and even life-threatening condition. The safest approach remains prompt evaluation and, when appropriate, a targeted short course of antibiotics.
A 2025 study in JAMA Network Open found that telehealth-treated UTIs had equivalent clinical outcomes to in-person visits, with significantly higher patient satisfaction scores and lower total cost of care. For uncomplicated UTIs — which make up the vast majority of cases — virtual evaluation is not just convenient; it's clinically sound.
Three out of four women will experience a vaginal yeast infection at some point. Despite being incredibly common, misconceptions about causes, treatment, and prevention persist. Here's what current research tells us.
A striking finding from a 2024 study in Obstetrics & Gynecology: up to two-thirds of women who self-treat with OTC antifungals don't actually have a yeast infection. Bacterial vaginosis, contact dermatitis, and even STIs can mimic yeast infection symptoms. Using the wrong treatment doesn't just waste money — it delays proper care and can worsen the underlying condition.
"Self-diagnosis of vaginal candidiasis is correct only about 34% of the time. Clinical evaluation, even via telehealth, dramatically improves diagnostic accuracy."— American Journal of Obstetrics & Gynecology, 2024
Emerging research on the vaginal microbiome is transforming how we think about yeast infections. A healthy vaginal microbiome is dominated by Lactobacillus species, which produce lactic acid and hydrogen peroxide to keep Candida in check. When this balance is disrupted — by antibiotics, hormonal changes, or other factors — Candida can overgrow.
Recent studies are exploring:
Oral fluconazole (Diflucan) continues to be the most effective treatment for uncomplicated yeast infections, with cure rates above 90%. A 2025 Cochrane review confirmed its superiority over topical-only treatments for both symptom relief speed and complete mycological cure.
For recurrent infections (four or more per year), current guidelines now recommend a 6-month suppressive regimen of weekly fluconazole, which reduces recurrence by approximately 90% during the treatment period.
Research has clarified which commonly repeated advice actually holds up:
If symptoms persist after treatment, or if you're experiencing recurrent infections, clinical evaluation is essential. Conditions like cytolytic vaginosis, lichen sclerosus, and desquamative inflammatory vaginitis can all present similarly and require different treatment approaches entirely.
Erectile dysfunction affects an estimated 30 million men in the U.S. and more than 150 million worldwide. Once a taboo subject, ED is now understood as a complex condition with significant implications beyond sexual health. Here's what the latest research reveals.
Perhaps the most important development in ED research is the growing evidence that erectile dysfunction often precedes cardiovascular disease by 3 to 5 years. A landmark 2024 study in the European Heart Journal followed over 200,000 men and confirmed that ED is an independent risk factor for heart attack, stroke, and cardiovascular mortality.
"Erectile dysfunction in men under 50 should be treated as a cardiovascular warning sign. These patients deserve metabolic and cardiac screening, not just a prescription."— European Heart Journal, 2024
This is why responsible ED treatment starts with a thorough health assessment — not just symptom relief.
Sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) remain the first-line treatment for most men with ED. Recent research has refined our understanding:
A 2025 meta-analysis in The Journal of Sexual Medicine found that depression and anxiety are both significant independent risk factors for ED, and that performance anxiety creates a self-reinforcing cycle. Importantly, the study found that treating the psychological component alongside medication improved outcomes by 40% compared to medication alone.
The research on lifestyle modifications is compelling:
ED was one of the first conditions where telehealth proved its value. A 2025 study in Urology found that men who used telehealth for ED treatment were 3x more likely to seek care in the first place — largely because of reduced embarrassment and convenience. Clinical outcomes were equivalent to in-person visits for uncomplicated cases, with significantly faster time to treatment.
Fluconazole — brand name Diflucan — is the most commonly prescribed oral treatment for vaginal yeast infections in the United States. A single 150 mg tablet resolves most uncomplicated yeast infections, but it doesn't flip a switch. Here's what the timeline actually looks like.
Fluconazole is absorbed quickly — peak blood levels are reached in 1 to 2 hours after you take it. But that's pharmacokinetics, not symptom relief. On day one, you've taken the pill and the drug is now circulating, but the fungal cells it's targeting are still very much alive. Most people feel exactly the same on day one as they did before the dose.
Fluconazole works by inhibiting an enzyme (lanosterol 14-alpha-demethylase) that yeast cells need to build their cell membranes. Without functional membranes, the yeast population starts to collapse. Clinically, most patients report noticeable improvement in itching, burning, and discharge between 24 and 72 hours after the dose. By day 3, about 80% of symptoms have resolved in uncomplicated cases.
Complete symptom clearance typically happens within 5 to 7 days. Some lingering mild irritation is normal during this window — the inflammatory response takes longer to settle than the infection itself.
If you're on day 5 and your symptoms haven't improved at all — or if they've gotten worse — that's a signal worth paying attention to. Possible reasons:
If you've had more than four yeast infections in a year, single-dose fluconazole likely isn't enough. Current guidelines support a longer induction course (150 mg every 72 hours for three doses) followed by weekly maintenance for up to six months. This is something your provider would discuss with you based on your history.
Short answer: yes — if "seeing a doctor" means sitting in a waiting room. You can't legally get antibiotics from a vending machine, but you can absolutely be evaluated and prescribed through async telehealth without ever physically meeting your provider. Here's how that actually works, and where it doesn't.
"Async" means you fill out a structured clinical intake on your phone or computer. A licensed medical provider — usually a physician or nurse practitioner — reads it, evaluates your symptoms against validated clinical criteria, and decides whether to prescribe. You and the provider never need to be on a call at the same time. Most async UTI visits are reviewed within a few hours.
It's different from a video visit (where you're on camera with the provider) and different from a chatbot (which is software, not a clinician). Async telehealth is real clinical decision-making by a real licensed human, just not in person and not in real-time.
UTIs are one of the best-studied conditions for async care. A 2025 study in JAMA Network Open compared async-treated and in-person-treated uncomplicated UTIs and found equivalent clinical outcomes, with significantly higher patient satisfaction and lower total cost in the async arm. That's because UTI diagnosis is heavily history-based: the pattern of symptoms (burning, urgency, frequency), combined with risk factors and a safety screen, is often enough for a confident diagnosis in otherwise-healthy patients.
Async isn't appropriate for every UTI. You need to see someone in person if you have:
A well-designed intake form will identify these cases and route you to in-person care rather than prescribe.
At Bidwell Health, a full async UTI visit is $45. That includes the clinical review and the prescription. No subscriptions, no insurance, no follow-up billing. Most urgent care visits for a UTI run $150–$250 before insurance; a primary care visit plus copay is often similar.
For appropriately selected cases: yes. The risk of async care is that a complicated case gets treated like an uncomplicated one. A well-designed intake form is the entire safety mechanism — it has to screen aggressively, and reject cases that need more workup. If a service is prescribing antibiotics to anyone who clicks the button, that's not async care, that's malpractice with extra steps.
Erectile dysfunction is probably the single most commoditized condition in US telehealth. You've seen the ads — same medications, confident branding, vague pricing. That's great when it works and dangerous when it doesn't. Here's what safe looks like, and what to walk away from.
Sildenafil (generic Viagra) and tadalafil (generic Cialis) are PDE5 inhibitors. They're remarkably safe for most men — but there are specific situations where they can cause serious problems. A legitimate online ED service screens for:
If a site doesn't ask about any of this, that's a red flag. It means they're not actually evaluating you — they're taking your money and sending a prescription.
Look for these specifics before handing over your card:
The FDA's safemedications.org has a list, but the short version: if a site offers to sell you sildenafil without any clinical evaluation, ships from outside the US, doesn't require a prescription, or has pricing that's way below every legitimate competitor — it's almost certainly selling counterfeit or contaminated product. Counterfeit sildenafil has been found containing drywall, printer ink, and fentanyl in documented FDA seizures.
ED can be an early warning sign of cardiovascular disease. If you have new-onset ED in your 40s or 50s, especially with other risk factors (high blood pressure, high cholesterol, diabetes, smoking), you should see a primary care provider for a cardiovascular workup — in addition to treating the symptom. Don't skip this step even if the pills "work."
Short answer: anywhere from $0 (if you have good insurance and infinite time) to around $350 (urgent care plus pharmacy). The honest ranges for the main options, as of 2026:
The typical walk-in urgent care visit for a simple UTI runs $150–$250 cash, plus the antibiotic ($8–$20 generic). If you have insurance, you're still likely paying your deductible or a $50–$100 copay. Time cost: 1–3 hours in the waiting room.
If you can get a same-day slot with your primary care provider, copays run $20–$80 with insurance, or $100–$250 cash. The catch is the wait — most primary care practices can't see you the same day. For a UTI, that's the wrong cadence.
If your insurance includes a telehealth benefit, virtual urgent care can be free or low-copay. Good option if you have it. Downside: the provider isn't always licensed in your state, the call quality is often poor, and the clinical pattern-match is "30-minute video visit" — overkill for a UTI that's easily treated from a structured intake.
Flat-fee services like Bidwell charge $45, Wisp is around $40, Ro varies. You fill out a structured clinical intake, a licensed provider reviews it in under 2 hours, and the Rx is sent to your pharmacy. No video call, no waiting room, no insurance forms. Your medication cost is whatever your pharmacy charges — typically $5–$20 for a generic UTI antibiotic.
The dominant hidden cost is time, not dollars. An urgent care visit is effectively a half-day. A primary care appointment is a waiting-week. Cash-pay async isn't the cheapest in pure dollars, but it's the lowest total-cost option once you price in your Saturday.
The other hidden cost is surprise billing. Urgent care centers are notorious for charging "facility fees" of $80–$150 on top of the visit, then sending a second bill 90 days later when your insurance declines coverage. Flat-fee means flat fee — what you pay is what you pay.
Yeast infections and bacterial vaginosis (BV) are the two most common causes of vaginal symptoms in women — and they're frequently confused, even by healthcare providers. Both cause itching, discharge, and discomfort. But the treatments are completely different, and treating one as the other can make it worse.
A yeast infection is an overgrowth of Candida, a fungus that normally lives on the body in small amounts. BV is a bacterial imbalance — the "good" lactobacilli lose ground to anaerobic bacteria like Gardnerella. Both happen when the vaginal microbiome gets disrupted (antibiotics, stress, new sexual partner, hormonal shifts), but the organisms — and the meds that kill them — are different species.
The single most useful clinical clue is the discharge itself:
Yeast infections itch. That's the dominant symptom — intense, persistent vulvar itching. BV often doesn't itch much; it's more about the odor and the thin discharge. Burning can happen with both, but itching-dominant = yeast, odor-dominant = BV.
BV often flares around your period or shortly after. Yeast infections tend to flare after antibiotic use, during pregnancy, or when you're immunocompromised (poorly controlled diabetes is a classic trigger).
Fluconazole (the standard yeast treatment) does nothing for BV. Metronidazole or clindamycin (the standard BV treatments) do nothing for yeast. If you grab OTC miconazole off the shelf for what's actually BV, you'll feel worse, spend more money, and delay real treatment. The inverse is also true — taking leftover metronidazole for a yeast flare can kill your lactobacilli even further and trigger a full yeast overgrowth.
Our intake form asks specifically about discharge color and consistency, presence of odor, and timing. If your answers look more like BV than yeast, we'll tell you — and recommend an in-person visit for BV (which genuinely benefits from a pelvic exam and speculum-collected pH test). We won't prescribe the wrong drug just to close a sale.